Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Merck & Co Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
MRK
New York
2834
https://www.merck.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Merck & Co Inc
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
- May 14th, 2024 1:25 pm
Merck cancels trial of melanoma treatment due to immune-mediated adverse events
- May 14th, 2024 9:21 am
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
- May 13th, 2024 5:09 pm
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
- May 13th, 2024 10:45 am
Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
- May 10th, 2024 11:00 am
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
- May 9th, 2024 1:00 pm
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
- May 9th, 2024 11:05 am
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
- May 9th, 2024 10:45 am
Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers
- May 8th, 2024 1:15 pm
Q1 2024 OPKO Health Inc Earnings Call
- May 8th, 2024 10:56 am
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
- May 8th, 2024 10:45 am
Gossamer sells rights to drug it hopes can rival a new Merck therapy
- May 6th, 2024 12:11 pm
Merck First Quarter 2024 Earnings: Beats Expectations
- May 6th, 2024 10:27 am
Here's Why Merck (MRK) is a Strong Momentum Stock
- May 3rd, 2024 1:50 pm
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
- May 2nd, 2024 6:53 pm
15 Best Places to Retire in Florida That You’ve Never Heard Of
- May 1st, 2024 10:52 pm
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- May 1st, 2024 11:15 am
3 Pharma Stocks With the Potential to Make You an Overnight Millionaire
- May 1st, 2024 10:24 am
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
- Apr 30th, 2024 12:44 pm
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
- Apr 29th, 2024 1:00 pm
Scroll